Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization

• DOI: 10.1038/onc.2017.132
• Publication Date: 2017-05-09T09:46:47Z
• Authors: H Guo; Q Zhu; X Yu; S B Merugu; H B Mangukiya; N Smith; Z Li; B Zhang; H Negi; R Rong; K Cheng; Z Wu; D Li
• Keywords: Oncogene Proteins; Ovarian Neoplasms; Vascular Endothelial Growth Factor A; 0301 basic medicine; 0303 health sciences; Neovascularization, Pathologic; Mice, Nude; Proteins; Angiogenesis Inhibitors; Apoptosis; Xenograft Model Antitumor Assays; 3. Good health; Bevacizumab; Mice; 03 medical and health sciences; Mucoproteins; Human Umbilical Vein Endothelial Cells; Animals; Humans; Female; Fibroblast Growth Factor 2; Protein Multimerization; Cells, Cultured; Cell Proliferation

The importance of the tumor microenvironment in targeted anticancer therapies has been well recognized. Various protein factors participate in the cross-talk between tumor cells and non-malignant cells. Anterior gradient-2 (AGR2) is overexpressed in diverse human adenocarcinomas and it exists in both intracellular and extracellular spaces. Although intracellular AGR2 has been intensively investigated, the function of secreted AGR2, especially its exact mechanism of action is still poorly understood. Here we report that the secreted AGR2 promotes the angiogenesis and the invasion of vascular endothelial cells and fibroblasts by enhancing the activities of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2). Further study indicated that AGR2 directly binds to these extracellular signaling molecules, and enhances their homodimerization. The extracellular AGR2 activity can be blocked to reduce angiogenesis and inhibit tumor growth in vitro and in vivo by a monoclonal antibody targeting the AGR2 self-dimerization region, and combined treatment with bevacizumab produced maximum inhibition effect. In conclusion, our investigation reveals a mechanism that directly links the secreted AGR2 with extracellular signaling networks, and we propose that the secreted AGR2 is a blockable molecular target, which acts as a chaperon-like enhancer to VEGF and FGF2.